

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)



(10) International Publication Number
WO 2022/246244 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/62 (2006.01)
A61P 35/00 (2006.01) A61K 39/00 (2006.01)
A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2022/030323

(22) International Filing Date:

20 May 2022 (20.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/191,488 21 May 2021 (21.05.2021) US
63/253,714 08 October 2021 (08.10.2021) US

(71) Applicant: **APTEVO RESEARCH AND DEVELOPMENT LLC** [US/US]; 2401 Fourth Ave., Suite 1050, Seattle, Washington 98121 (US).

(72) Inventors; and


(71) Applicants: **UCKUN, Faith** [—/US]; c/o Aptevo Research and Development LLC, 2401 Fourth Ave., Suite 1050, Seattle, Washington 98121 (US). **STROMATT, Scott** [—/US]; c/o Aptevo Research and Development LLC, 2401 Fourth Ave., Suite 1050, Seattle, Washington 98121 (US).

(74) Agent: **MCLEOD, Bonnie, Weiss et al.**; Cooley LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: DOSING REGIMENS FOR PROTEIN THERAPEUTICS

FIG. 12



(57) Abstract: Provided herein are methods for treating a cancer, the methods comprising administering to a subject in need thereof: i) a multispecific protein comprising a CD123 binding domain and a CD3 binding domain; and ii) a second anti-cancer agent. The anti-cancer agent used in the methods described herein, may be, for example a chemotherapeutic drug. In some embodiments, the chemotherapeutic drug is venetoclax, azacitidine, decitabine, daunorubicin, cytarabine, idarubicin, mitoxantrone, or etoposide.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*